Differentiated thyroid cancer: A new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients

Thyroid

Volumn 24, Issue 4, 2014, Pages 715-726

  Versari, Annibale ^a   Sollini, Martina ^a   Frasoldati, Andrea ^b   Fraternali, Alessandro ^a   Filice, Angelina ^a   Froio, Armando ^a   Asti, Mattia ^a   Fioroni, Federica ^a   Cremonini, Nadia ^c   Putzer, Daniel ^d   Erba, Paola Anna ^e  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b IRCCS   (Italy)

^c MAGGIORE HOSPITAL   (Italy)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EDOTREOTIDE; EDOTREOTIDE GALLIUM GA 68; EDOTREOTIDE Y 90; FLUORODEOXYGLUCOSE F 18; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; 111IN-DOTA-TOC; 90Y-OCTREOTIDE, DOTA-TYR(3)-; GA(III)-DOTATOC; OCTREOTIDE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CONTROL; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFERENTIATED THYROID CANCER; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; NAUSEA; NEPHROTOXICITY; PATIENT SELECTION; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DIAGNOSTIC USE; METABOLISM; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; SCINTISCANNING; THYROID NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898492814     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0225     Document Type: Article

References (64)

1. Haugen BR 1999 Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 16:34-41
2. Baudin E, Schlumberger M 2007 New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 8:148-156
3. Grúnwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, Risse J, Biersack HJ 1998 Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 39:1903-1906
4. Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, Goretzki PE, Roeher HD 1998 Redifferentiation therapy with retinoids: Therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 22:569-574
5. Kogai T, Taki K, Brent GA 2006 Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer 13:797-826
6. Venkataraman GM, Yatin M, Marcinek R, Ain KB 1999 Restoration of iodide uptake in dedifferentiated thyroid carcinoma: Relationship to human Na+/I- symporter gene methylation status. J Clin Endocrinol Metab 84:2449-2457
7. Short SC, Suovuori A, Cook G, Vivian G, Harmer C 2004 A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin Oncol (R Coll Radiol) 16:569-574
8. Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, Lobo M, Cotter P, Duh QY, Clark OH 2005 Troglitazone, the peroxisome proliferator-activated receptor gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15:222-231
9. Antonelli A, Ferri C, Ferrari SM, Sebastiani M, Colaci M, Ruffilli I, Fallahi P 2010 New targeted molecular therapies for dedifferentiated thyroid cancer. J Oncol 2010:921682
10. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R, Nutting CM 2011 Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: A phase II study in a UK based population. Eur J Endocrinol 165:315-322
11. Kapiteijn E, Schneider TC, Morreau H, Gelderblom H, Nortier JW, Smit JW 2012 New treatment modalities in advanced thyroid cancer. Ann Oncol 23:10-18
12. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA 2013 Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368:623-632
13. Giammarile F, Houzard C, Bournaud C, Hafdi Z, Sassolas G, Borson-Chazot F 2004 Diagnostic management of suspected metastatic thyroid carcinoma: Clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans. Eur J Endocrinol 150:277-283
14. Sancak S, Hardt A, Singer J, Klöppel G, Eren FT, Gúllúoglu BM, Sen LS, Sever Z, Akalin NS, Eszlinger M, Paschke R 2010 Somatostatin receptor 2 expression determined by immunohistochemistry in cold thyroid nodules exceeds that of hot thyroid nodules, papillary thyroid carcinoma, and Graves' disease. Thyroid 20:505-511
15. Krohn K, Stricker I, Emmrich P, Paschke R 2003 Cold thyroid nodules show a marked increase in proliferation markers. Thyroid 13:569-575
16. Krohn K, Paschke R 2002 Somatic mutations in thyroid nodular disease. Mol Genet Metab 75:202-208
17. Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Hörsch D, O'Dorisio MS, O'Dorisiol TM, Howe JR, Cremonesi M, Kwekkeboom DJ 2013 The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40:800-816
18. De Jong M, Bernard BF, De Bruin E, Van Gameren A, Bakker WH, Visser TJ, Mácke HR, Krenning EP 1998 Internalization of radiolabeled [DTPA0]octreotide and [DOTA0, Tyr3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 19:283-288
19. Eberle AN, Mild G 2009 Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods. J Recept Signal Transduct Res 29:1-37
20. Waldherr C, Schumacher T, Pless M, Crazzolara A, Maecke HR, Nitzsche EU, Haldemann A, Mueller-Brand J 2001 Radiopeptide transmitted internal irradiation of noniodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. Nucl Med Commun 22:673-678
21. Görges R, Kahaly G, Müller-Brand J, Mácke H, Roser HW, Bockisch A 2011 Radionuclide-labeled somatostatin ana- logues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 11:647-659
22. Iten F, Muller B, Schindler C, Rasch H, Rochlitz C, Oertli D, Maecke HR, Muller-Brand J, Walter MA 2009 [(90)Yttrium- DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: Kong-term results of a phase 2 clinical trial. Cancer 115:2052-2062
23. Teunissen JJ, Kwekkeboom DJ, Krenning EP 2006 Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab 17:19-25
24. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
25. Filice A, Fraternali A, Frasoldati A, Asti M, Grassi E, Massi L, Sollini M, Froio A, Erba PA, Versari A 2012 Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: A single experience. J Oncol 2012:320198
26. Asti M, Atti G, Iori M, Farioli D, Filice A, Versari A 2012 semiautomated labelling and fractionation of yttrium-90 and lutetiom-177 somatostatin analogues usind disposable syringes and vials. Nucl Med Commun 33:1144-1152
27. Stabin MG, Sparks RB, Crowe E 2005 OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023-1027
28. Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, Maecke HR, Jermann E, Robertson C, Fiorenza M, Tosi G, Paganelli G 1999 Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: Implications for internal radiotherapy with 90Y-DOTATOC. Eur J Nucl Med 26:877-886
29. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, de Camps J, Schran H, Chen T, Smith MC, Bouterfa H, Valkema R, Krenning EP, Kvols LK, Pauwels S 2003 (86YDOTA0)- D-Phe1-Tyr3-octreotide (SMT487) - A phase 1 clinical study: Pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid coinfusion. Eur J Nucl Med Mol Imaging 30:510-518
30. National Cancer Institute 2006 Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: Http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev3.pdf (accessed August 9, 2006).
31. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
32. Postema PT, De Herder WW, Reubi JC, Oei HY, Kwekkeboom DJ, Bruining HJ, Bonjer J, van Toor H, Hennemann G, Krenning EP 1996 Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion 57:36-37
33. Haug AR, Auernhammer CJ, Wá ngler B, Schmidt GP, Uebleis C, Göke B, Cumming P, Bartenstein P, Tiling R, Hacker M 2010 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 51:1349-1356
34. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803
35. Bannas P, Derlin T, Groth M, Apostolova I, Adam G, Mester J, Klutmann S 2012 Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan? Ann Nucl Med 26: 77-85
36. Hoelting T, Duh QY, Clark OH, Herfarth C 1996 Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo. J Clin Endocrinol Metab 81:2638-2641
37. Siperstein AE, Levin KE, Gum ET, Clark OH 1992 Effect of somatostatin on adenylate cyclase activity in normal and neoplastic thyroid tissue. World J Surg 16:555-561
38. Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, Von Guggenberg E, Kendler D, Virgolini IJ 2010 Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging 54: 92-99
39. Pazaitou-Panayiotou K, Tiensuu Janson E, Koletsa T, Kotoula V, Stridsberg M, Karkavelas G, Karayannopoulou G 2011 Somatostatin receptor expression in nonmedullary thyroid carcinomas. Hormones (Athens) 11: 290-296
40. Valsamaki P, Gotzamani-Psarrakou A, Tsiouris S, Molyvda- Athanasopoulou E, Psarrakos K, Papantoniou V, Gerali S, Zerva C 2006 Tc-99m depreotide imaging of I-131-negative recurrent metastatic papillary thyroid carcinoma. Int J Cancer 119:968-970
41. Garin E, Devillers A, Le Cloirec J, Bernard AM, Lescouarc'h J, Herry JY, Reubi JC, Bourguet P 1998 Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur J Nucl Med 25:687-694
42. Ahlman H, Tisell LE, Wángberg B, Fjá lling M, Forssell- Aronsson E, Kölby L, Nilsson O 1997 The relevance of somatostatin receptors in thyroid neoplasia. Yale J Biol Med 70:523-533
43. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J 2002 Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43:610-616
44. Middendorp M, Selkinski I, Happel C, Kranert WT, Grúnwald F 2010 Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: Preliminary data. Q J Nucl Med Mol Imaging 54:76-83
45. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A 2010 Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga- DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37:2004-2010
46. Kowalski J, Henze M, Schuhmacher J, Maecke HR, Hofmann M, Haberkorn U 2003 Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D-Phe1-Tyr3- octreotide in compar- ison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5:42-48
47. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Scháfer M, Schilling T, Haufe S, Herrmann T, Haberkorn U 2007 Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34:1617-1626
48. Wierts R, de Pont CD, Brans B, Mottaghy FM, Kemerink GJ 2011 Dosimetry in molecular nuclear therapy. Methods 55:196-202
49. Vinjamuri S, Gilbert TM, Banks M, McKane G, Maltby P, Poston G, Weissman H, Palmer DH, Vora J, Pritchard DM, Cuthbertson DJ 2013 Peptide receptor radionuclide therapy with 90Y-DOTATATE/90Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: Assessment of response, survival and toxicity. Br J Cancer 108:1440-1448
50. Zhang Y, Jia S, Liu Y, Li B, Wang Z, Lu H, Zhu C 2007 A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun 28:251-255
51. Ma C, Kuang A, Xie J, Ma T 2005 Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J Nucl Med 46:1473-1480
52. Gulec SA, Suthar RR, Barot TC, Pennington K 2011 The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging 38:1289-1295
53. Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ 2009 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 50:1427-1434
54. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PP, Bakker WH, Lasher J, Krenning EP 2005 Long-term follow-up of renal function after peptide receptor radiation therapy with (90)YDOTA Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)- octreotate. J Nucl Med 46:83S-91S
55. Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, Perren A 2009 Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 36:48-52
56. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP 2008 Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0, Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 26:2124-2130
57. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, Bartolomei M, Lombardo D, Ferrari ME, Sansovini M, Chinol M, Paganelli G 2011 Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study. Eur J Nucl Med Mol Imaging 38:2125-2135
58. Teunissen JJ, Kwekkeboom DJ, Krenning EP 2004 Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol 22:2724-2729
59. Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, Nihashi T, Nagai H 2006 Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: A systematic review. J Clin Oncol 27:1906-1914
60. Juweid ME, Cheson BD 2006 Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354: 496-507
61. Obrzut S, Bykowski J, Badran K, Hayeri MR, Hoh CK 2010 Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response. Nucl Med Commun 31:1008-1015
62. Herrmann K, Benz MR, Krause BJ, Pomykala KL, Buck AK, Czernin J 2011 (18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: Where we are and where we can go. Q J Nucl Med Mol Imaging 55:620-632
63. Yanagawa M, Tatsumi M, Miyata H, Morii E, Tomiyama N, Watabe T, Isohashi K, Kato H, Shimosegawa E, Yamasaki M, Mori M, Doki Y, Hatazawa J 2012 Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J Nucl Med 53:872-880
64. Sobin LH, Gospodarowicz MK, Wittekind C (Eds) 2009 TNM Classification of Malignant Tumours, 7th ed. John Wiley & Sons/UICC, New York.